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Lipoprotein Analysis in Practice?
Jennifer G. Robinson, MD, MPH
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Some practitioners use advanced lipoprotein analysis with the goal of better predicting risk and individualizing
lifestyle and drug therapy for cardiovascular prevention. Unfortunately, low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) particle number and size, other lipoprotein subfractionation, apolipoproteins B and A,
and lipoprotein(a) have not yet met current standards for biomarker evaluation, and it remains to be determined
whether these tests incrementally add to cardiovascular risk predicted by traditional risk factors. More impor-
tantly, it has yet to be determined whether treatment strategies guided by, or targeting, these measures improve
cardiovascular outcomes. Drug therapies known to alter advanced lipoprotein analysis parameters, specifically niacin
and fenofibrate, have not been shown to additionally reduce cardiovascular risk in recent randomized trials of high-
risk patients treated with statin therapy. These findings suggest advanced lipoprotein analysis–guided strategies may
not further reduce cardiovascular events and could lead to increased adverse effects and costs; this approach needs
further research to establish its role in individualizing therapies for cardiovascular prevention. In contrast, a large body
of evidence supports focusing on LDL cholesterol reduction and intensification of statin therapy to reduce cardiovas-
cular risk. (J Am Coll Cardiol 2012;60:2607–15) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.067Clinicians continue searching for biomarkers that will facil-
itate the practice of personalized preventive medicine. Al-
gorithms for predicting cardiovascular risk using traditional
risk factors, such as the Framingham Risk Score recom-
mended by the National Cholesterol Program Adult Treat-
ment Panel III, provide an estimate of the probability that
a patient will experience a coronary heart disease (CHD)
event in the next 10 years. In contrast, the clinician would
like an ideal biomarker, or biomarkers, that would give a
definitive prediction (yes or no) of the individual patient’s
risk of cardiovascular disease (CVD) to guide the intensity
and type of therapy. For example, the Framingham Risk
See page 2616
Score might estimate that a 45-year-old man with low-density
lipoprotein cholesterol (LDL-C) of 125 mg/dl has a 5% risk of
CHD in the next 10 years (1). The Adult Treatment Panel III
recommendations would not consider him a candidate for
lipid-modifying drug treatment (2). Additionally, he is too
young (50 years) and his C-reactive protein is too low (1.5
mg/dl) to meet the JUPITER (Justification for the Use of
Statins in Prevention: an Intervention Trial Evaluating Rosu-
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2012, accepted April 18, 2012.vastatin) entry criteria (3). However, if an ideal biomarker
could determine whether this person could be the 1 of 20
patients who go on to have a CHD event in the next 10 years,
the clinician could then initiate more intensive lifestyle and/or
drug therapy to reduce this patient’s cardiovascular risk. Con-
versely, if the biomarker were absent, the patient would then be
among the 19 patients who do not experience a CHD event in
the next 10 years, and drug treatment, and possibly more
aggressive lifestyle changes, could be avoided.
Treatment guided by advanced lipoprotein analysis is 1
approach advocated by some to identify additional lipid and
lipoprotein biomarkers to guide the initiation, type, and
intensity of lipid-modifying therapy beyond the recommen-
dations of the current guidelines (3–5). The rationale for this
approach is that a substantial proportion of patients continue to
have events, a concept promoted as “residual risk”. Some
advanced lipoprotein analysis results have been incorporated
into the most recent dyslipidemia guidelines, including apoli-
poprotein (apo) B, apo A-I, and lipoprotein(a) (Lp[a]) (6–8).
This paper reviews whether there is sufficient evidence to
support the use of advanced lipoprotein analysis as an ideal
biomarker to better predict risk and to make personalized
treatment decisions in individual patients, and future research
directions are recommended (Table 1).
What Does Advanced
Lipoprotein Analysis Measure?
Advanced lipoprotein analysis quantitates subpopulations of
lipoproteins and apos, including particle size and number,
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and high-density lipoprotein
(HDL) particle number and size
and apos B and A have been sug-
gested as more reliable measures of
atherogenicity than LDL-C or
non–HDL-C (a measure of
atherogenic triglyceride-rich apos
calculated when triglycerides are
between 200 and 500 mg/dl by
subtracting HDL-C from total
cholesterol) (1).
The cholesterol content of
LDL particles varies substan-
tially between patients, and pa-
tients with the same LDL-C
level may have very high or low
numbers of LDL particles. Each
LDL particle contains 1 mole-
cule of apo B-100 (apo B). The
relationship between the number
of apo A-I molecules and HDL
is less direct (9). The size of the
LDL and HDL particles is closely
related to cholesterol and triglyceride
concentrations. Cholesterol, largely
transported through the body as
LDL-C, has clearly been established
as a causal agent in atherosclerosis over many decades of extensive
research (10). Regardless of size, LDL particles are atherogenic.
Large LDL particles predominate in those with familial
hypercholesterolemia (patients who are at risk of very prema-
ture coronary events) and those consuming high fat diets
(11,12). Some epidemiological studies found that small LDL
particles are more atherogenic than large ones, but this rela-
Abbreviations
and Acronyms
apo  apolipoprotein
CHD  coronary heart
disease
CI  confidence interval
CIMT  carotid intima
media thickness
CVD  cardiovascular
disease
ER  extended-release
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
Lp(a)  lipoprotein(a)
NMR  nuclear magnetic
resonance
Non–HDL-C  non–high-
density lipoprotein
cholesterol
QALYs  quality-adjusted
life-years
VAP  vertical auto profile
VLDL-C  very low-density
lipoprotein cholesterol
Agenda for Establishing the Role ofdvanced Lipoprotein Analysis in IndividualizingTreatm nt for P ev ting Cardiovascular Disease
Table 1
Agenda for Est blishing the Rol of
Advanced Lipoprotein Analysis in Individualizing
Treatment for Preventing Cardiovascular Disease
Establish international standards for measurement
Establish improved predictive accuracy compared with conventional methods
Discrimination (improves receiver-operating curve or C-statistic compared with
conventional method)
Calibration (observed risk consistent across deciles of predicted risk)
Reclassification (better classifies subjects as low, moderate, or high risk, or as
crossing various treatment thresholds, than conventional methods)
Identification of subgroups of patients in whom advanced lipoprotein analysis
better predicts risk
Establish that advanced lipoprotein analysis–guided treatment reduces
cardiovascular events more than conventional treatment strategies
Identification of subgroups of patients for whom advanced lipoprotein
analysis–guided treatment reduces risk more than currently recommend
treatment strategies
Establish superior benefit-cost ratio of advanced lipoprotein analysis for
screening and guiding treatment compared with conventional strategies
Establish advanced lipoprotein analysis improves clinical implementation of risk
reduction strategies
Favorably influences patient behavior
Favorably influences physician behaviortionship usually disappears in more fully adjusted analyses,
including insulin resistance–associated factors, including dia-
betes, hypertriglyceridemia, low HDL-C, and apo B (12).
Ratios of apos have also been proposed as better predictors of
cardiovascular risk than conventional lipid levels or ratios (13).
Lp(a) is a plasma protein composed of an LDL particle linked
to apo(a), which has structural homology with plasminogen.
Lp(a) may therefore contribute to both intimal cholesterol
deposition and prothrombotic potential.
Advanced Lipoprotein
Analysis Methods and Performance
No standardized laboratory methods for lipoprotein subclass
distribution and quantitation have been established
(12,14,15). The currently available commercial laboratory
methods use a variety of methods to measure lipoprotein
subfractions: gradient gel electrophoresis (Berkeley Heart
Lab, Inc., Berkeley, California), nuclear magnetic resonance
(NMR) (Liposcience, Inc, Raleigh, North Carolina), den-
sity gradient rapid ultracentrifugation (termed the “vertical
auto profile” [VAP]; Atherotec, Birmingham, Alabama),
and most recently, microfluidic gel electrophoresis using a
chip technology (Quest Diagnostics Inc., Madison, New
Jersey). Each method measures different physiochemical
properties, such as size, charge, distribution of cholesterol,
or magnetic resonance to estimate lipoprotein subclass
distribution. An Agency for Healthcare Research and Quality–
funded systematic review of reports published through June
2008 found widely varying agreement among methods
(ranging from 7% to 94% concordance) for measuring LDL
subfractions, such that measurements using different meth-
ods were not directly comparable (14).
In contrast, international standards exist for apos B and
A-I. Apo B measurement with immunoassays (immunotur-
bidometric, immunonephelometric, and radial immunodif-
fusion) have similar accuracy (16). However, VAP and
NMR are the most commonly used methods for advance
lipid testing, including apo B and A-I measurement, and
have more variability. A 2011 study of1,000 patients with
combined hyperlipidemia and significant hypertriglyceride-
mia (those in whom measurement of conventional and
advanced lipid measures are considered most discordant
[17]) found that total apo B levels were highest using an
immunonephelometric assay (Medical Research Laboratory
International, Inc., Highland Heights, Kentucky), interme-
diate with NMR (14% lower than the immunonephelomet-
ric assay), and lowest with VAP (about 17% lower than the
immunonephelometric assay) (18). Conversely, non–
HDL-C levels were similar across the assays.
Measurement of Lp(a) has long been problematic due to
interindividual variation in the number of kringles deter-
mining the length of the apo(a) moiety, which accounts for
90% of the plasma concentration of Lp(a) (19). Only
recently have recommendations been made to standardize
Lp(a) assays using apo(a) isoform insensitive assays that are
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was recently approved. However, there are large race-
dependent variations in Lp(a) levels, and reference ranges
for individual race/ethnicities have yet to be developed (19).
Modern standardized assays for plasma total cholesterol
and HDL-C use standardized methods based on the current
Centers for Disease Control and Prevention reference
methods; these methods should result in a coefficient of
variation of 4% for calculated LDL-C (20). Small sea-
sonal and long-term variations in LDL-C in statin-treated
patients have been described (21,22). Whether similar
changes occur in the components of advanced lipoprotein
analysis have not yet been established.
Advanced Lipoprotein Analysis for
Cardiovascular Disease Risk Prediction
Several recent systematic reviews and meta-analyses have
evaluated the various components of advanced lipoprotein
analysis for cardiovascular risk prediction. The previously
noted Agency for Healthcare Research and Quality system-
atic review found each Lipoprotein subfractionation method
used different criteria and definitions to classify the CHD
risk of patients (14). No studies comparing the accuracy of
various methods for predicting CVD risk were identified.
The American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guide-
lines more recently completed a systematic review of liter-
ature published between March 2008 and April 2010 (9).
They found that the LDL particle number was found in
many, but not all, studies to be independently associated
with CVD outcomes after adjustment for established risk
factors. Although LDL particle number predicted risk
better than LDL-C, the risk predicted by LDL particle
number was similar to that of more comprehensive measures
of atherogenic particles, such as non–HDL-C or apo B.
Subsequent to these meta-analyses, an analysis of the
MESA (Multi-Ethnic Study of Atherosclerosis) trial,
which included 6,814 subjects free of CVD followed for 5.5
years, found that LDL-C and LDL particle number were
associated with incident CVD in the overall cohort (23).
However, only LDL particle number was associated with
CVD risk in those whose LDL-C and LDL particle
number differed by 12 percentage points (termed “discor-
dant”). Not surprisingly, those who were discordant with
the LDL particle number greater than LDL-C concentra-
tion had higher body mass index, waist circumference,
measures of insulin resistance, and more frequently had
metabolic syndrome and diabetes. No comparisons of LDL
particle number to non–HDL-C or apo B were performed
in this analysis. However, another analysis of MESA
compared the ratio of total cholesterol/HDL-C with the
ratio LDL particle number/HDL-C particle number (24).
Both ratios were similarly excellent predictors of increased
CVD risk, but the addition of the LDL particle number/
HDL-C particle ratio did not meaningfully improve the HC-statistic of the Framingham Risk Score based on total
cholesterol and HDL-C levels. Nor did the LDL particle
number/HDL-C particle ratio result in the net reclassifica-
tion index of at-risk patients (0.1%).
Recent meta-analyses of apo B for CVD risk prediction
had conflicting conclusions. The Emerging Risk Factors
Collaboration performed an individual-level meta-analysis
of 302,430 subjects free of vascular disease (25). Individual-
level meta-analyses are generally considered more robust
than study-level meta-analyses for a number of reasons,
including many more data points and the ability to adjust
for covariates at the individual level. In the 22 studies that
measured both apos and lipids, the apo B and the apo B/A-I
ratio had very similar magnitudes of association as non–
HDL-C and the total-C/HDL-C ratio after adjustment for
other established risk factors.
A subsequent study-level meta-analysis by Sniderman et
al. (26) included 15 studies and 233,455 subjects with and
without CHD. Although the 95% confidence intervals
(CIs) overlapped, the relative risk reduction in CVD events
for lowering apo B were on average 6% higher than those for
lowering non–HDL-C, and the relative risk reductions for
lowering non–HDL-C were 5% higher than for lowering
LDL-C. In contrast to the previous Emerging Risk Factors
Collaboration individual-level analysis (25), no adjustment
for other established risk factors was performed. However,
in the small number of reports by population subgroup,
there was no evidence that the relationship between apo B
and non–HDL-C varied by diabetes status in the Snider-
man et al. (26) trial-level analysis, one of the patient
populations in whom apo B was considered by advocates to
improve risk prediction.
The studies comparing advanced lipoprotein analysis-
based risk prediction to conventional risk prediction meth-
ods (such as Framingham Risk Score), according to current
standards for novel biomarker assessment, including dis-
crimination, calibration, and reclassification (Table 1) (27),
ound no added risk prediction over conventional lipid mea-
urements. In the previously described EPIC (European Pro-
pective Investigations into Cancer and Nutrition)-Norfolk
tudy, although the apo B/A-I ratio was independently asso-
iated with increased CHD risk, it did no better than conven-
ional lipid values at discriminating between CHD cases
nd control subjects (area under the receiver-operating
haracteristic curve: 0.673 vs. 0.670, respectively; p  0.38)
28). When the apo B/A-I ratio was added to the Framing-
am score, the area under the receiver-operating character-
stic curve was slightly increased (0.613 with vs. 0.594
ithout; p  0.001). However, addition of the apo B/A-I
atio to the Framingham score resulted in incorrect classi-
cation of 41% of CVD cases and 50% of control subjects
ithout CVD. Another analysis of the Framingham study
ad similar findings (29). Another analysis found that
lthough lipoprotein particle, LDL, HDL, very low-density
ipoprotein (VLDL) LDL/HDL concentration, and LDL,
DL, and VLDL particle size measured by NMR each
p
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risk factors, these measures were not superior to total-C,
LDL-C, HDL-C, apo B, apo A-I, or the apo B/A-I ratio
(30). The addition of LDL particle size or apo B did not
improve the C-index, nor did LDL particle size or apo B
result in reclassification compared with a model that con-
tained the total cholesterol, HDL-C, and nonlipid risk
factors. Another analysis of a subgroup of women from the
this study used an immunoturbidometric method to mea-
sure apos B and A-I and found that it had the same
magnitude of risk prediction as non–HDL-C, both of
which were superior to LDL-C (31). Moreover, HDL-C
appeared to be a better risk predictor than apo A-I.
In summary, the various parameters of advanced lipopro-
tein analysis do not appear to improve CVD prediction over
risk prediction strategies using conventional lipid measure-
ments when evaluated according to current standards for
biomarker evaluation.
Advanced Lipoprotein Analysis for
Cardiovascular Disease Risk Prediction
in Drug-Treated Patients
Based on an extensive body of evidence, statins are the
evidence-based treatment of choice, with statin treatment
initiation based on LDL-C and risk level (1,2,32). There-
fore, a more clinically applicable use of advanced lipoprotein
analysis is for risk prediction in statin-treated patients to
guide further intensification of lipid therapy. To examine
this concept in patients with CHD receiving statin therapy,
an analysis pooling the TNT (Treating to New Targets) and
IDEAL (Incremental Decrease in Endpoints Through
Aggressive Lipid Lowering) study populations found that
on-treatment levels of non–HDL-C and apo B were better
predictors of CVD risk reduction from statin treatment
than on-treatment LDL-C levels (33). In addition, in those
with LDL-C 100 mg/dl on statin therapy, non–HDL-C
and apo B identically predicted CVD risk. Furthermore, in
those with non–HDL-C 130 mg/dl or apo B 110
mg/dl, non–HDL-C and apo B levels had almost identical
risk prediction performance. Another analysis from the
PROVE-IT (Pravastatin or Atorvastatin Evaluation and
Infection Therapy - Thrombolysis in Myocardial Infarction
22) trial also found that on-treatment non–HDL-C pro-
vided additional risk prediction over on-treatment LDL-C
levels, but the on-treatment apo B/AI ratio did not (34).
Two analyses evaluated primary prevention statin trials.
In the AFCAPS/TexCAPS (Air Force/Texas Coronary
Atherosclerosis Prevention Study) trial, on-treatment per-
cent changes in LDL-C, HDL-C, and apo B did not
predict CHD risk reduction, although percent change in
apo A1 and apo B/A-I did (35). Comparing on-treatment
levels, the achieved apo B and apo B/A-I ratio predicted
CHD risk reduction better than achieved LDL-C level, but
no comparison was made to on-treatment non–HDL-C
level. In JUPITER, those on rosuvastatin 20 mg who had anon-treatment C-reactive protein 2 mg/l were at lower risk
regardless of apo B above or below 80 mg/dl (36); con-
versely, in those with C-reactive protein 2 mg/l, those
with apo B 80 mg/dl were at higher risk than those with
apo B 80 mg/dl.
A recent individual-level meta-analysis pooled data from
8 primary and secondary prevention statin trials, including
the 4S (Simvastatin Survival Study), AFCAPS, LIPID
(Long-term Intervention with Pravastatin in Ischaemic
Disease), CARDS (Collaborative Atorvastatin Diabetes
Study), TNT, IDEAL, SPARCL (Stroke Prevention by
Aggressive Reduction of Cholesterol Levels), and JUPITER
(n  38,153) trials (37). Changes in non–HDL-C and apo
B in statin-treated patients similarly predicted reduction in
CVD risk slightly better than LDL-C. Changes in non–
HDL-C and apo B similarly predicted CVD reduction in
all subpopulations studied, including those with diabetes
and triglycerides 150 or 150 mg/dl. Interestingly, the
roportion of the treatment effect explained by the reduc-
ion in non–HDL-C (64%) was greater than that explained
y the reduction in apo B (54%; p  0.007) or LDL-C
(50%; p  0.001).
In summary, all patients requiring cholesterol-lowering
drug therapy for CVD risk reduction should receive a statin
as first-line therapy. Change in non–HDL-C appears to be
superior to apo B or LDL-C changes for predicting the
magnitude of CVD reduction in statin-treated patients.
Treatment Outcomes
Regardless of whether advanced lipoprotein analysis im-
proves cardiovascular risk prediction (although there is
evidence that it may not, as reviewed previously), the most
important question is whether therapeutic strategies guided
by advanced lipoprotein analysis improve outcomes com-
pared with fixed-dose therapy or compared with strategies
titrating to LDL-C and/or non–HDL-C goals. Unfortu-
nately, no clinical trials have yet been performed to answer
this question. However, observational evidence is available
from randomized trials. Although the SANDS (Stop Ath-
erosclerosis in Native Diabetics Study), ACCORD (Action
to Control Cardiovascular Risk in Diabetes), and AIM-
HIGH (The Atherothrombosis Intervention in Metabolic
syndrome with low HDL/high triglycerides) trials did not
use advanced lipoprotein analysis to direct treatment, these
trials evaluated whether combining a statin with a second
lipid-modifying agent with significant effects on advanced
lipoprotein analysis parameters would improve cardiovascu-
lar outcomes compared with statin monotherapy. A careful
evaluation of these trials may yield helpful information for
determining the role of advanced lipoprotein analysis for
guiding the intensity of therapy.
SANDS. SANDS randomized participants with type 2
diabetes to either aggressive treatment (LDL-C70 mg/dl,
non–HDL-C 100 mg/dl, and systolic blood pressure
115 mm Hg) or standard treatment (LDL-C 100
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sure 130 mm Hg) targets (38). The treatment algorithm
started with lifestyle modification, then added a statin if
needed; if the LDL-C goal was not achieved on a statin,
ezetimibe was added; if the non–HDL-C goal was not
achieved on a statin, fish oil, fenofibrate, or niacin were
added. After 3 years of treatment in SANDS, carotid intima
media thickness (CIMT) regressed in the aggressive treat-
ment group and progressed in the standard treatment group.
LDL-C, non–HDL-C, triglycerides, and apo B were sig-
nificantly reduced in the aggressive treatment group com-
pared with the standard treatment group, as were total,
medium, and small VLDL-P; VLDL size; total, small, and
large LDL particles; and apo B (39). There were no
differences in HDL-C; large VLDL particles; LDL size;
total, large, and small HDL-C; or HDL size between the 2
groups. Decreases in both LDL-C (p  0.005) and non–
HDL-C (p  0.012) were correlated with CIMT regres-
sion. Apo B had similar associations as non–HDL-C across
quartiles, but did not quite achieve statistical significance
(p  0.07). In contrast, reduction in LDL particles had no
consistent relationship with CIMT regression and was not
significant (p  0.09). It should be noted that greater
CIMT regression was seen in those in the aggressive group
who achieved an LDL-C 73 mg/dl.
ACCORD. The ACCORD trial compared more intensive
treatment with standard treatment for diabetes control,
lipids, and blood pressure in patients with type 2 diabetes
(40). In the ACCORD lipid trial, all participants received
background open-label simvastatin and were randomized to
fenofibrate or placebo, with a 4.7-year follow-up (41). At
baseline, LDL-C levels were 101 mg/dl, and by the end of
the trial, mean LDL-C levels were very similar in both
treatment groups (81 vs. 80 mg/dl, respectively). At base-
line, median glycosylated hemoglobin levels were 8.1%, and
were reduced to 7.5% in the standard therapy and to 6.4%
in the intensive glycemic control groups. All major lipid
parameters continued to improve in both treatment arms
during the trial, possibly as a result of better glycemic
control. By trial end, mean HDL-C levels increased from
38.0 to 41.2 mg/dl in the fenofibrate group and from 38.2
to 40.4 mg/dl in the placebo group; median triglyceride
levels decreased from 164 to 122 mg/dl in the fenofibrate
group and from 160 to 144 mg/dl in the placebo group. No
differences in the primary cardiovascular outcome (hazard
ratio: 0.92; 95% CI: 0.79 to 1.08; p  0.32) or any
secondary outcome were found. In prespecified subgroup
analyses, there was a suggestion of harm in women, but a
benefit in men (interaction p  0.01) and a suggestion of
benefit in those with both HDL-C 34 mg/dl and triglyc-
erides 204 mg/dl (but no benefit in those without;
interaction p  0.057). The low HDL-C/high triglyceride
subgroup comprised only 17% of the study population with
well-controlled type 2 diabetes.
Advanced lipoprotein analyses have not yet been per-formed in the ACCORD trial. Therefore, a systematicreview was undertaken using PubMed to identify
fenofibrate-statin efficacy trials measuring particle size,
number, apos, or Lp(a). A 12-week efficacy trial in 300
dyslipidemic diabetic participants had baseline and on-
treatment lipid levels fairly similar to those in the AC-
CORD trial and evaluated changes in particle number and
size (VAP II) (42,43). The on-treatment levels on simva-
statin 20 mg in this trial (LDL-C 92 mg/dl, HDL-C 39
mg/dl, triglycerides 183 mg/dl, and non–HDL-C 130
mg/dl) were fairly similar to those observed at baseline in
the ACCORD trial, where 65% of patients were on a lipid
medication at baseline (60% on a statin) and were not
washed out. In comparison to the ACCORD trial, baseline
lipids were LDL-C 101 mg/dl, HDL-C 38 mg/dl, triglyc-
erides 160 to 164 mg/dl, and non–HDL-C 137 mg/dl (41).
Fenofibrate 160 mg added to simvastatin 20 mg further
reduced LDL pattern B (LDL3  LDL4) 4 mg/dl (6%),
ncreased buoyant LDL (LDL1  LDL2, also known as
pattern A) by 14 mg/dl (33%), increased HDL3 by 3.4
g/dl (11%), increased dense VLDL 3.9 mg/dl (16%), and
ncreased intermediate-density lipoprotein 2.5 mg/dl (10%).
either treatment had an effect on Lp(a).
Contrasting the effect of fenofibrate-statin combination
ith high-intensity statin therapy, an analysis comparing
ipoprotein subclasses (VAP II), apo B, and conventional
ipid markers found that both atorvastatin 80 mg and the
ombination drugs ezetimibe 10 mg  atorvastatin 40 mg
educed LDL-C, the cholesterol content of most LDL
ubfractions (LDL1–4), apo B, and non–HDL-C (44,45).
However, these treatments did not reduce the proportion of
smaller, more dense, LDL particles. The proportion of
pattern B increased in patients with triglycerides 150 and
150 mg/dl. Note that atorvastatin 80 mg was shown to
reduce CVD events in 3 clinical trials that enrolled20,000
subjects (46–48). Therefore, use of alternate therapy, such
as the simvastatin plus fenofibrate used in the ACCORD
trial, based on pattern B information might lead to the use
of less efficacious therapy than atorvastatin 80 mg or other
intensive LDL-C lowering agents in many patients.
The ACCORD trial found that the majority of diabetic
patients with LDL-C levels 100 mg/dl (the mean in the
ACCORD trial was about 80 mg/dl in both treatment
groups) and reasonably well-controlled diabetes and blood
pressure were unlikely to experience any benefit from the
addition of fenofibrate to a moderate-dose statin. The pro-
jected changes in particle size and number from the addition
of fenofibrate were unlikely to have contributed any addi-
tional risk reduction to the LDL-C lowering from simva-
statin therapy. It has yet to be determined whether the very
small subgroup of patients in the ACCORD trial with low
HDL-C along with high triglcyerides would benefit more
from intensive statin therapy than they did from lower dose
statin therapy combined with fenofibrate. The mean dose of
simvastatin in the ACCORD trial was 22 mg/dl in both the
fenofibrate and placebo groups. As previously noted, both
the TNT and IDEAL trials found atorvastatin 80 mg
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therapy (simvastatin 20 to 40 mg or atorvastatin 10 mg) and,
in contrast to the ACCORD trial, these trials found a
substantial significant reduction in CVD events in the
atorvastatin 80 mg group, regardless of baseline HDL-C or
triglyceride levels (46,48).
In terms of non-cardiovascular outcomes, fenofibrate was
shown to reduce the risk of retinopathy progression (al-
though it did increase creatinine) in the FIELD (Fenofi-
brate Intervention and Event Lowering in Diabetes) trial,
but no such data were available for atorvastatin (49).
Therefore, in the absence of a trial comparing statin-
fenofibrate therapy to intensive statin therapy (such as
atorvastatin 80 mg or another statin that lowers LDL-C by
approximately 50%), or trials titrating therapy to advanced
lipoprotein testing parameters, intensive statin therapy
should remain the treatment of choice in dyslipidemic
patients and in those with diabetes.
AIM-HIGH. The purpose of the AIM-HIGH trial was
to determine whether adding niacin to simvastatin was
superior to simvastatin alone for reducing cardiovascular risk
in dyslipidemic patients with CVD who had similar on-
treatment LDL-C levels (50). The AIM-HIGH trial ran-
domized 3,414 participants to extended-release (ER) niacin
1,500 to 2,000 mg/day or a matching placebo (with 50 to
100 mg of immediate-release niacin to maintain the blind).
Both groups received simvastatin 40 mg at baseline, the
dose of which could be adjusted, or ezetimibe was added, to
achieve an LDL-C of 40 to 80 mg/dl. Simvastatin 40 mg
was received by 50% of participants in both groups (simva-
statin 80 mg by 28% of the placebo group and 18% of the
ER niacin group). Ezetimibe 10 mg was received by 21.5%
of the placebo group and 9.5% of the ER niacin group. At
1 year, the mean LDL-C was 66  20 mg/dl in the ER
niacin group and 70  19 mg/dl in the placebo group.
When the change from baseline was compared between the
2 groups, the niacin group had 14% higher HDL-C, 23%
lower triglycerides, 16% lower non–HDL-C, 10% lower apo
B, 5% higher apo A, 19% lower Lp(a), 50% higher HDL2,
and 10% higher HDL3.
The AIM-HIGH trial was terminated early with a
median 3 years of follow-up due to futility, as well as a
nonsignificant excess of strokes in the niacin group. Al-
though the trial was criticized for its relatively small sample
size, the survival curves were directly superimposable: a
longer trial would have been highly unlikely to reveal a
separation of the survival curves, and hence was terminated.
Therefore, it could reasonably be concluded from the
AIM-HIGH trial that niacin-induced changes in non–
LDL–C lipid parameters (including, it should be noted,
non–HDL-C). In patients with well-controlled LDL-C,
niacin appeared to provide no additional cardiovascular risk
reduction benefit. A strategy of simvastatin plus ER niacin
1,500 to 2,000 mg (with or without ezetimibe) appeared
equivalent to simvastatin (with or without ezetimibe), which
achieved on-treatment LDL-C of 40 to 80 mg/dl. AIM- cHIGH therefore suggests that use of niacin to target various
lipid fractions other than LDL-C might provide no partic-
ular advantage and might increase adverse effects (signifi-
cant cutaneous adverse effects as well as less commonly
serious muscle symptoms, gout, atrial fibrillation, type 2
diabetes, and gastric ulcers) and costs (discussed in the next
section) (50,51). In addition, in the AIM-HIGH trial, a
nonsignificant excess of strokes was observed in the ER
niacin group (30 vs. 18 in the placebo group; hazard ratio:
1.67; 95% CI: 0.93 to 2.99; p  0.09) (50). The importance
f this finding was unclear, because 8 of the strokes in the
iacin group occurred after niacin was discontinued between
months and 4 years. No excess of stroke was observed in
he Coronary Drug Project, a trial comparing approximately
g immediate-release niacin with placebo in men with
HD and hypercholesterolemia (52).
It was argued that HDL-C levels did not differ enough
etween the ER niacin-simvastatin and placebo-simvastatin
roups. However, on the basis of previous epidemiological
tudies where each 1 mg/dl increment in HDL-C was
ssociated with a 2% to 3% reduction in CHD risk (53), it
as expected to see at least some difference (albeit perhaps
ot significant) in the survival curves if the 5.2 mg/dl
DL-C in the ER niacin group reduced CVD risk by 10%
o 16%. After examining the AIM-HIGH trial results, it is
ore difficult to support the argument of advocates of
dvanced lipoprotein analysis to intensify treatment to
mprove all abnormal parameters, because this argument
ssumes that such improvements would be additive to the
ncrease in HDL-C. It should also be noted that apo B
as 80 mg/dl in both the ER niacin group and placebo
roups of the AIM-HIGH trial. An apo B 80 mg/dl
as identified as the third target of therapy, after LDL-C
nd non–HDL-C, for the highest risk patients in a joint
tatement from the American Diabetes Association and
merican College of Cardiology (6).
Another observation is that in both the ACCORD and
IM-HIGH trials, the majority of participants were on
tatin therapy at baseline (60% and 93%, respectively) (48).
n the AIM-HIGH trial, 76% were on a statin 1 year.
ong-term statin therapy has been shown to stabilize
laque, and it might be difficult to demonstrate additional
enefit from incremental lipid changes in these patients. For
xample, after the 2 years of simvastatin 40 mg therapy in
he ASAP (Atorvastatin versus Simvastatin on Atheroscle-
osis) trial, no further reduction in CIMT was observed
fter 2 more years of follow-up when the simvastatin 40
roup was switched to atorvastatin 80 mg (54).
ost Effectiveness
cost-effectiveness analysis of the SANDS trial found the
ore aggressive treatment group had slightly lower medical
osts than the standard group, but 54% greater costs for
ntihypertensive medications ($1,242) and 116% greater
osts for lipid-lowering medications ($2,863) over 3 years
a
f
(
m
c
a
r
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adjusted life-years (QALYs) over the standard group. How-
ever, at a 3% discount rate, a cost per QALY of $82,589
would not be considered cost effective. Alternate scenarios
reducing the cost of medications by 25%, 50%, and 75%
resulted in cost per QALY of $61,329, $40,070, and
$18,810, respectively, suggesting that exclusive use of lower
cost generic medications could make aggressive treatment of
LDL-C, non–HDL-C, and blood pressure a cost-effective
option at a threshold of $50,000 per QALY. It is unlikely
that even more aggressive therapy targeting additional
lipoprotein parameters (e.g., apo B was proposed [7]), if it
requires additional full-cost patent-protected drugs, will be
cost effective unless large reductions in cardiovascular events
occur.
Conclusions and Research Recommendations
Proponents of advanced lipoprotein analysis argue that:
1) these tests lend further insight into important distur-
bances in lipid metabolism that explain the failure of
LDL-C lowering strategies to eliminate cardiovascular
events; and 2) therapies directed toward correcting the
residual risk due to these abnormalities will further reduce
cardiovascular risk. Unfortunately, these 2 hypotheses may
be fundamentally flawed for a number of reasons. First,
many of the lipoprotein and apo abnormalities detected
with advanced lipoprotein analysis are the result of insulin
resistance, and the excess cardiovascular risk associated with
many of the advanced lipoprotein analysis abnormalities in
epidemiological studies largely disappears after more com-
plete adjustment for insulin resistance–related characteris-
tics, including adiposity, hyperglycemia, hypertension, hy-
pertriglyceridemia, and low HDL-C, and physical
inactivity. These insulin-resistance characteristics are al-
ready assessed by the clinician in routine practice. Lifestyle
intervention is the most appropriate strategy for reducing
residual risk due to insulin resistance; several diabetes
prevention trials demonstrated marked reductions in pro-
gression to diabetes with moderate weight loss and increas-
ing moderate aerobic physical activity (56). It is not clear
how intensification of drug therapies directed specifically at
correcting lipid abnormalities would improve an insulin
resistant state. Second, it is not clear how correcting lipid
abnormalities would address the residual risk of other
well-established cardiovascular risk factors, such as aging,
male sex, hypertension, or smoking.
Third, it is not clear that advanced lipoprotein testing
dds much information to what is already known from a
asting lipid panel, despite significant additional cost
57). Non–HDL-C is calculated from total cholesterol
inus HDL-C at no additional charge, and appears to
apture the information provided by advanced lipoprotein
nalysis measures.
Fourth, it seems naïve to believe that patients withesidual risk due to an advanced burden of atherosclerosiswill be “cured” with the 5 or so years of LDL-C lowering
that occurred in the statin trials. Most of those arguing for
residual risk in statin trials quote only a 30% reduction in
cardiovascular events in the statin trials. Although this is
accurate for moderately intensive statin therapy, more in-
tensive statin therapy that lowers LDL-C by 50% (such as
atorvastatin 80 mg or rosuvastatin 20 mg) has been shown
to reduce cardiovascular risk by about 45% compared with
placebo, even when baseline LDL-C levels are 130 mg/dl
(3,46–48). Meta-analysis of the statin trials found the
reduction in cardiovascular events to be directly related to
the magnitude of LDL-C lowering, with every 39 mg/dl
(1 mmol/l) resulting in an additional 22% reduction in
cardiovascular events across a wide range of baseline
LDL-C levels (32). Therefore, intensification of statin
therapy should be used as the first-line approach for more
aggressive lipid management. If a patient has lipid abnor-
malities on a more intensive statin, the benefits, harms, and
benefit–cost ratio of additional of second or third agents has
yet to be established. Also of concern is how the additional
agents, or more intensive LDL-C lowering, will influence
the very modest increased risk of incident diabetes observed
with statin therapy (about 1 to 3 additional diabetes cases
per 1,000 patients treated per year) (3,58).
Fifth, although assessment of advanced lipoprotein anal-
ysis parameters such as apo B, LDL particle number, and
Lp(a) have been advocated by some as reasonable for many
intermediate- and high-risk patients (59), to date, clinical
trial data do not support the superiority of treatment
strategies incorporating nonstatin lipid-modifying agents
compared with intensive statin therapy. The AIM-HIGH
trial found that niacin-induced non–LDL-C lipoprotein
and apo changes were not associated with further improve-
ment in outcomes when LDL-C was lowered to 40 to 80
mg/dl, nor did ACCORD find overall benefit from adding
fenofibrate to a lower dose of simvastatin in a dyslipidemic
population of diabetic patients with mean LDL-C levels of
80 mg/dl, despite what were likely substantial changes in
LDL-C particle size distribution and VLDL levels. A
surrogate endpoint trial found reductions in non–HDL-C,
and apo B predicted improvements in CIMT, but the LDL
particle number did not; moreover, the aggressive statin-
based treatment strategy used in this trial was only cost
effective if generic medications were used (38).
In summary, in the current evidence-based practice en-
vironment, there is insufficient evidence to support the use
of advanced lipoprotein analysis in clinical practice. Basic
requirements for diagnostic and prognostic testing in clin-
ical practice have yet to be met by many of the parameters
measured in advanced lipoprotein analysis, nor has advanced
lipoprotein analysis met the most important criteria needed
to incorporate a new biomarker, technology, or treatment
into clinical practice, which is, “Does this additional infor-
mation improve clinical outcomes?” In the absence of evidence
of improved clinical outcomes, benefit–cost analysis cannot be
performed.
2614 Robinson JACC Vol. 60, No. 25, 2012
Role of Advanced Lipoprotein Analysis December 25, 2012:2607–15Table 1 outlines a research agenda for establishing the
role of advanced lipoprotein analysis in individualizing
therapy to prevent CVD. Outcomes from trials evaluating
strategies based on advanced lipoprotein analysis will also
need to include adverse effects, quality of life, and benefit–
cost analyses, especially as the population at risk for CVD
becomes increasingly diverse and advanced in age.
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